INVESTOR RELATIONS
As featured in the media
* STOCKHEAD – HeraMED secures landmark commercial agreement with Joondalup Health Campus
* THEMARKERLAND – HeraMED (ASX:HMD) arranges tech pilot at Joondalup Health Campus
* THE SENTIMENT- High-touch, high-quality maternity care could soon become standard in major hospitals
Latest Announcements
* For additional information about share price and latest announcements please review HeraMED’s page on the ASX platform View Page
- JHCs Clinical Trial Published in Nature Portfolio 07/11/2022View
- Quarterly Activities & Cashflow Report28/10/2022View
- Notification regarding unquoted securities – HMD 25/10/2022View
- Notification regarding unquoted securities – HMD 25/10/2022View
- Notification regarding unquoted securities – HMD 25/10/2022View
- Cleansing Notice 25/10/2022View
- Application for quotation of securities – HMD25/10/2022View
- Results of Annual General Meeting 12/10/2022View
- Initial Director’s Interest Notice – Emily Slade13/09/2022View
- Appointment of Emily Slade as a Non-Executive Director13/09/2022View
- Notice of Annual General Meeting/Proxy Form09/09/2022View
- Cleansing Notice 31/08/2022View
- Application for quotation of securities – HMD31/08/2022View
- Appendix 4D and Half Year Report26/08/2022View
- Proposed issue of securities – HMD24/08/2022View
- HeraMED Completes $4 Million Private Placement24/08/2022View
- Trading Halt22/08/2022View
- Notification of cessation of securities – HMD18/08/2022View
- Notification of cessation of securities – HMD16/08/2022View
- Notification regarding unquoted securities – HMD02/08/2022View
- Quarterly Activities & Cashflow Report 29/07/2022View
- HMD & e-Lovu Health Partnership for HeraCARE Deployment US 28/07/2022View
- Notification of cessation of securities – HMD26/07/2022View
- HMD Appoints New Head of ANZ Strategic Partnerships26/07/2022View
- HMD Part of Team Providing Telemedicine Solutions West Bank18/07/2022View
- Notification regarding unquoted securities – HMD08/07/2022View
- Notification regarding unquoted securities – HMD07/06/2022View
- Notification regarding unquoted securities – HMD05/05/2022View
- Notification regarding unquoted securities – HMD04/05/2022View
- Outstanding Results Achieved in Second JHC Clinical Trial02/05/2022View
- Cleansing Notice29/04/2022View
- Application for quotation of securities – HMD29/04/2022View
- Quarterly Activities & Cashflow Report29/04/2022View
- Investor Presentation – April 202226/04/2022View
- HMD-Pediatrix Virtual OB Pilot Shows Promising Results 19/04/2022View
- Appendix 4G and Corporate Governance Statement29/03/2022View
- Annual Report to shareholders29/03/2022View
- Notification of cessation of securities – HMD01/03/2022View
- Appendix 4E & Preliminary Final Report25/02/2022View
- Notification of cessation of securities – HMD25/02/2022View
- Cleansing Notice21/02/2022View
- Application for quotation of securities – HMD21/02/2022View
- Quarterly Activities & Cashflow Report30/01/2022View
- Cleansing Notice28/01/2022View
- Application for quotation of securities – HMD28/01/2022View
- Reinstatement to Official Quotation21/01/2022View
- JHC agrees to full commercial rollout of HeraCARE21/01/2022View
- Suspension from Official Quotation20/01/2022View
- Trading Halt18/01/2022View
- Pause in Trading18/01/2022View
- Results of Meeting20/12/2021View
- Notification of cessation of securities – HMD10/12/2021View
- Notification of cessation of securities – HMD10/12/2021View
- Cleansing Notice09/12/2021View
- Application for quotation of securities – HMD09/12/2021View
- Change of Director’s Interest Notice x 307/12/2021View
- Cleansing Notice07/12/2021View
- Application for quotation of securities – HMD07/12/2021View
- Cleansing Notice02/12/2021View
- Application for quotation of securities – HMD02/12/2021View
- Notice of General Meeting/Proxy Form18/11/2021View
- Update on Placement Capacity15/11/2021View
- Response to ASX Price Query15/11/2021View
- Cleansing Notice29/09/2021View
- Quarterly Activities & Cashflow Report29/09/2021View
- Appendix 3G28/09/2021View
- Proposed issue of securities – HMD18/09/2021View
- $2.39 million raised via a Convertible Note18/09/2021View
- Trading Halt14/09/2021View
- Positive Interim Results US Paid Pilot & 2nd Site Confirmed13/09/2021View
- HeraCARE Shortlisted for Government tender in Spain01/09/2021View
- Appendix 4D and Half Year Report 27/08/2021View
- Cleansing Prospectus16/08/2021View
- Sheba Expands Pilot to include High-Risk Pregnancies02/08/2021View
- Quarterly Activities & Cashflow Report29/07/2021View
- Results of Meeting 23/07/2021View
- Change of Registered Office19/07/2021View
- Update – Notice of Extraordinary General Meeting19/07/2021View
- HeraCARE paid pilot commences with US-based Obstetrix Group19/07/2021View
- Application for quotation of securities – HMD14/07/2021View
- Application for quotation of securities – HMD30/06/2021View
- Notice of Extraordinary General Meeting/Proxy Form23/06/2021View
- Notification regarding unquoted securities – HMD 15/06/2021View
- Appendix 3G15/06/2021View
- Results of Annual General Meeting31/05/2021View
- Chairman’s letter to shareholders 31/05/2021View
- Updated Investor Presentation and Webinar17/05/2021View
- Pilot agreement signed with US leader Obstetrix Medical 13/05/2021View
- Trading Halt11/05/2021View
- Appendix 2A03/05/2021View
- Notice of Annual General Meeting/Proxy Form29/04/2021View
- Quarterly Activities & Cashflow Report28/04/2021View
- HeraCARE commercial agreement with Joondalup Health Campus22/04/2021View
- Trading Halt20/04/2021View
- Appendix 4G and Corporate Governance Statement 29/03/2021View
- Annual Report to shareholders29/03/2021View
- JHC’s Study Published One of Most Cited Scientific Journals Link to journals Link to Poadcast 15/03/2021View
- Appendix 4E & Preliminary Final Report 26/02/2021View
- Becoming a substantial holder18/02/2021View
- Appendix 2A & Cleansing Notice10/02/2021View
- Israel’s Largest Healthcare Provider Begins Pilot Study08/02/2021View
- Proposed issue of Securities – HMD04/02/2021View
- Proposed issue of Securities – HMD04/02/2021View
- Completion of AUD 2.3M Placement04/02/2021View
- Trading Halt02/02/2021View
- Quarterly Activities & Cashflow Report29/01/2021View
- Hapvida Extends Subscription on new SaaS Terms26/01/2021View
- Updated HeraMED Investor Update Conference Call17/12/2020View
- HeraMED Investor Update Conference Call 17/12/2020View
- Mayo Clinic approves Clinical Study of HeraBEAT 15/12/2020View
- Partnership to Launch HeraCARE & HeraBEAT with Teleperinatal 15/12/2020View
- Appendix 2A14/12/2020View
- Release from escrow23/11/2020View
- Partnership with eCare21 – Additional Information 16/11/2020View
- Partnership with eCare21 & functional integration complet08/11/2020View
- Quarterly Activities & Cashflow Report29/10/2020View
- Amended Updated Investor Presentation21/10/2020View
- Updated Investor Presentation21/10/2020View
- HMD Clinical Study Results Conference Call08/10/2020View
- Clinical & Functional Validation of HeraBEAT Achieved at JHC08/10/2020View
- Partnership with Leading Virtual Care Platform eCare21 in US16/09/2020View
- Appendix 2A07/09/2020View
- Enrolment in Clinical Study at JHC Completed Ahead Schedule03/09/2020View
- Appendix 4D and Half Year Report25/08/2020View
- Proposed issue of Securities – HMD14/08/2020View
- Proposed issue of Securities – HMD14/08/2020View
- Appendix 2A11/08/2020View
- Appendix 2A11/08/2020View
- Cleansing Notice05/08/2020View
- Proposed issue of Securities – HMD05/08/2020View
- Successful Placement of SPP Shortfall05/08/2020View
- Updated Quarterly Activities Report03/08/2020View
- Change of Director’s Interest Notice03/08/2020View
- Quarterly Activities & Cashflow Report29/07/2020View
- Study Commenced & Recruitment Initiated – Joondalup Campus27/07/2020View
- Change of Director’s Interest Notice23/07/2020View
- Appendix 2A21/07/2020View
- Reinstatement to Official Quotation21/07/2020View
- Proposed issue of Securities – HMD21/07/2020View
- Proposed issue of Securities – HMD21/07/2020View
- Proposed issue of Securities – HMD21/07/2020View
- HeraMED Extends its Collaboration with Mayo Clinic21/07/2020View
- Suspension from Official Quotation20/07/2020View
- Trading Halt16/07/2020View
- Pause In Trading16/07/2020View
- Results of Annual General Meeting14/07/2020View
- Results of Share Purchase Plan Offer13/07/2020View
- Final Approvals Received to Commence Clinical Study13/07/2020View
- Update on HMD SPP Offer25/06/2020View
- Becoming a substantial holder24/06/2020View
- Appendix 2A and Cleansing Notice15/06/2020View
- Letter to Shareholders regarding Notice of AGM12/06/2020View
- Notice of Annual General Meeting/Proxy Form12/06/2020View
- HMD SPP Offer Booklet and Application Form12/06/2020View
- SPP Cleansing Notice12/06/2020View
- Appendix 3B05/06/2020View
- Company Presentation – June 202005/06/2020View
- HMD Raises $2.32 Million and Launches SPP05/06/2020View
- Trading Halt01/06/2020View
- Agreement with Freeman Rd & PHI Group – Pilots in Australia20/05/2020View
- Exclusive Agreement Executed with Australian Distributor08/05/2020View
- Quarterly Activities and CashFlow Report01/05/2020View
- New FDA Recommendations – Fetal & Maternal Monitoring27/04/2020View
- Appendix 2A & Cleansing Notice17/04/2020View
- US Market Entry Strategy Update07/04/2020View
- US Market Strategy Presentation – April 202007/04/2020View
- Appendix 4G and Corporate Governance Statement27/03/2020View
- Annual Report to shareholders27/03/2020View
- HMD Update & COVID-19 Opportunities Conference Call25/03/2020View
- Company Update – COVID-19 To Accelerate Global Opportunities24/03/2020 View
- HeraCARE Product Development Update02/03/2020 View
- HeraCARE Presentation – March 202002/03/2020 View
- Change of Company Secretary & Registered Address02/03/2020 View
- Appendix 4E & Preliminary Final Report27/02/2020 View
- Cleansing Notice20/02/2020 View
- Appendix 2A19/02/2020 View
- Proposed issue of Securities – HMD19/02/2020View
- Results of General Meeting19/02/2020View
- HeraBEAT Plus Clinical Trial Study Details17/02/2020View
- Mayo Clinic clinical study to evaluate HeraBEAT Plus10/02/2020View
- HeraMED appoints US General Manager of Operations03/02/2020View
- December Quarter Activities Report and Appendix 4C30/01/2020View
- Notice of Extraordinary General Meeting and Proxy Form20/01/2020View
- HMD accesses unique pregnancy database to strengthen OrionAI20/01/2020View
- Response to ASX Aware Query20/01/2020View
- Update on Voluntary Escrow for Minor Vendor Options09/01/2020View
- Cleansing Notice17/12/2019View
- Appendix 3B17/12/2019View
- Appendix 3B12/12/2019View
- A$1.42m strategic placement completed to expedite US entry10/12/2019View
- Trading Halt06/12/2019View
- New CPT codes allow for potential reimbursement in USA04/12/2019View
- 2020 Company Outlook02/12/2019View
- Change of Director’s Interest Notice – Tal Slonim28/11/2019View
- Change of Director’s Interest Notice – David Groberman28/11/2019View
- Appendix 3B and ASX Escrow Release28/11/2019View
- Indian Hospital Group Cooperates with H-Cube and HeraMED25/11/2019View
- Release of Securities from ASX Escrow Restriction20/11/2019View
- HeraMED Receives FDA 510(k) Clearance for HeraBEAT Device18/11/2019View
- Retraction of Statements – Next Tech Stock Article15/11/2019View
- Trading Halt15/11/2019View
- Pause in Trade15/11/2019View
- Response to ASX Price and Volume Query14/11/2019View
- Trading Halt14/11/2019View
- Pause in Trading14/11/2019View
- Hapvida Saude (Brazil) Trial Update07/11/2019View
- Appendix 3B05/11/2019View
- September Quarter Activities Report and Appendix 4C30/10/2019View
- Market entry for HeraBEAT and HeraCARE Progresses in India25/10/2019View
- HeraCARE – the digital era of pregnancy care14/10/2019View
- Collaboration agreement secured with IntMED Software Ltd ME02/10/2019View
- HMD passes first stage for Israel Innovation Authority Grant24/09/2019View
- HeraMED and Mayo Clinic to co-develop a New Platform17/09/2019View
- Global Distribution Progress Update04/09/2019View
- Appendix 3B28/08/2019View
- HeraMED Solutions Operational Across Multiple Hapvida Sites28/08/2019View
- Appendix 4D and Half Year Report28/08/2019View
- Correction to Appendix 4C14/08/2019View
- HeraMED enters the German market with initial PO secured12/08/2019View
- June Quarterly Activities Report & Appendix 4C31/07/2019View
- HeraCARE Investor Presentation July 201922/07/2019View
- HeraCARE PRO Integrated into Hapvidas Hospital Systems01/07/2019View
- HeraBEAT Australian B2C launch underway19/06/2019View
- Appendix 3B14/06/2019View
- Appendix 3B06/06/2019View
- Appendix 3B03/06/2019View
- Release of Securities from Escrow31/05/2019View
- Results of Annual General Meeting29/05/2019View
- Annual General Meeting Venue Room Update24/05/2019View
- Dr Friedman joins HeraMED advisory board20/05/2019View
- HeraMED to launch HeraBEAT in Mexico15/05/2019View
- Company Presentation May 201914/05/2019View
- Release of Securities from Escrow09/05/2019View
- HeraMED Expands European Distribution Network Clarification08/05/2019View
- HeraMED Expands European Distribution Network08/05/2019View
- HeraMED begins FDA Approval Process for HeraBEAT29/04/2019View
- Notice of Annual General Meeting and Proxy Form26/04/2019View
- March Quarterly Activity Report & Appendix 4C26/04/2019View
- Meerkats Partners for HeraBEATs Australian B2C Launch16/04/2019View
- HeraMED launches HeraBEAT in the United Kingdom11/04/2019View
- Response to ASX Query – Annual Report as at 31/12/1808/04/2019View
- Addendum to Annual Report05/04/2019View
- Appendix 4G29/03/2019View
- Annual Report29/03/2019View
- Orion Artificial Intelligence Presentation26/03/2019View
- Dr Arturo Weschler MD Appointed to Lead Orion AI Operations26/03/2019View
- Quasar Manufacturing Agreement to Deliver Scale & Efficiency13/03/2019View
- Appendix 4E & Preliminary Final Report28/02/2019View
- Major Brazilian Health Care Group Places Initial Pilot Order14/02/2019View
- December Quarterly Activity Report & Appendix 4C31/01/2019View
- Australian Distribution Agreement for 9000 HeraBEAT Units14/01/2019View
- December Investor Presentation19/12/2018View
- Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
- HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
- Becoming a substantial holder – Tal Slonim11/12/2018View
- Becoming a substantial holder – David Groberman11/12/2018View
- Initial Director’s Interest Notice – Tal Slonim11/12/2018View
- Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
- Initial Director’s Interest Notice – Doron Birger11/12/2018View
- Initial Director’s Interest Notice – David Hinton11/12/2018View
- Initial Director’s Interest Notice – David Groberman11/12/2018View
- Statement of Confirmations10/12/2018View
- Updated Statement of Commitments10/12/2018View
- Voluntary Escrow10/12/2018View
- Restricted Securities10/12/2018View
- Updated Pro Forma Statement of Financial Position10/12/2018View
- Capital Structure10/12/2018View
- Securities Trading Policy10/12/2018View
- Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
- Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
- Supplementary Prospectus10/12/2018View
- Prospectus10/12/2018View
- Constitution10/12/2018View
- Appendix 1A and Information Form and Checklist10/12/2018View
- Top 20 Holders10/12/2018View
- Distribution Schedule10/12/2018View
- ASX Notice – Admission to Official List10/12/2018View